# Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

> **NCT01051063** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Leukaemia, Myelocytic, Acute

## Interventions

- **BIOLOGICAL:** GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A

## Key facts

- **NCT ID:** NCT01051063
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-09
- **Primary completion:** 2016-04-26
- **Final completion:** 2016-04-26
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051063, "Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01051063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*